This is a randomized, double-blind, placebo-controlled, dose escalation study to assess the safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day for three weeks in people with CF who are 18 years and older. The treatment duration in this study is intended to provide multi-dose safety information prior to proceeding to longer durations of exposure.
>= 18 Years
40 - 90 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
The Children's Hospital/University of Alabama at Birmingham (Pediatric), Birmingham, AL, 35233
Hathorne, Heather Phone: (205) 638-9568 Email: firstname.lastname@example.org
National Jewish Health (Adult), Denver, CO, 80206
Jones, Marion Phone: (303) 398-1265 Email: email@example.com
University of North Carolina at Chapel Hill (Pediatric), Chapel Hill, NC, 27599
Barlow, Carol Phone: (919) 966-9146 Email: firstname.lastname@example.org
University Hospitals Case Medical Center/Rainbow Babies and Children's Hospital (Pediatric), Cleveland, OH, 44106
Ksenich, Roberta (Bobbi) Phone: (216) 844-5733 Email: Roberta.Ksenich@UHHospitals.org
Medical University of South Carolina (Adult), Charleston, SC, 29425
Warden, Ashley Phone: (843) 792-4349 Email: email@example.com